These findings hold particular relevance for GLP-1 non-responders, providing crucial insights into alternative treatment pathways
de Germay S, Pambrun E, Pariente A, Grenet G, Bezin J, Faillie JL (2024) Use of sodium-glucose cotransporter-2 inhibitors in France: analysis of French nationwide health insurance database
Moderate Dose Range (40-80 mcg): This represents the most often used dose range in research protocols
The advantages of these options include more affordability and flexibility, especially for those without insurance
Not advised in severe kidney or stomach motility disorders
GLP-1 Side Effects: Gastrointestinal Issues, Bone Loss, and More Aside from weight loss, one of the most well-known facts about these drugs are its other side effects, with the most commonly known one being gastrointestinal distress due the nature of how the drugs work